Organon extends Adventis' contract to handle UK contraceptive portfolio

Organon has appointed Adventis Group's marketing, design and advertising subsidiary Roundhouse HealthAd to provide advertising and marketing support for all of its contraceptive products and launch a new contraceptive option in the UK.

Roundhouse has a long-standing relationship with Organon and already handles the promotional activities for Cerazette (ethinyl estradiol / desogestrel), the first oestrogen-free pill, as well as the long-acting contraceptive implant Implanon (etonogestrel).

Roundhouse will provide an advertising campaign for the launch of an as yet unnamed new contraceptive, which uses an innovative delivery option.

Organon in the UK is one of only three pharmaceutical companies substantially involved in R&D into new contraceptive methods.

Kevin McGetrick, managing director of Roundhouse, commented: "We have produced some of our best work for Organon and we are delighted that they have entrusted with all their contraceptive products. Choosing a contraceptive is a very personal issue and all women have different needs. We take a more consumer-orientated approach, which requires a different discipline to the way we promote most prescription medicines. This makes the work both challenging and stimulating!"

Charles Phillpot, CEO of Adventis, added: "I am delighted by this development and it underlines the enduring relationships we have and look to develop with our clients. We now work on both advertising (Roundhouse) and medical education projects (Leapfrog Medical communications) for Organon and it shows how the Adventis healthcare offering can provide a total range of solutions for our clients."